Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA060050-03
Application #
2100658
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1994-03-01
Project End
1999-02-28
Budget Start
1996-03-01
Budget End
1997-02-28
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Oostra, Drew R; Lustberg, Maryam B; Reinbolt, Raquel E et al. (2015) Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Mol Cell Endocrinol 402:51-6
Gordon, Angela M; Hurwitz, Shelley; Shapiro, Charles L et al. (2011) Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer. Menopause 18:1244-8
Shapiro, C L; Halabi, S; Hars, V et al. (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683-9
Breedlove, Hollie A; Smith, Anne M; Burk, Raymond F et al. (2006) Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure. Breast Cancer Res Treat 97:225-30
Shapiro, Charles L; Phillips, Gary; Van Poznak, Catherine H et al. (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90:41-6
Shapiro, C L; Manola, J; Leboff, M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-11